Day: June 11, 2022

Loretta Rogers 1939 - 2022

Loretta Rogers 1939 – 2022

TORONTO, June 11, 2022 (GLOBE NEWSWIRE) — It is with great sorrow that Rogers Communications Inc. (“Rogers”) today announces the passing of Loretta Rogers at the age of eighty-three, peacefully in her home, surrounded by family.  A beloved wife to the late Ted Rogers, mother, and grandmother, Loretta lived a full and vibrant life who dedicated herself to family, friendship, community and business. Loretta believed passionately in Ted’s vision for the company, and through 45 years of a deeply loving marriage, Loretta and Ted supported each other to grow Rogers into the company that it is today. Following Ted’s death, Loretta devoted herself to keeping his vision alive and making Rogers the absolute best it could be.   Mrs. Rogers served as a corporate director of Rogers Communications since 1964 and was a member of the...

Continue reading

HII Christens Richard M. McCool Jr. (LPD 29)

HII Christens Richard M. McCool Jr. (LPD 29)

Richard M. McCool Jr. (LPD 29) Christening Ship’s Sponsors Shana McCool and Kate Oja christened Richard M. McCool Jr. (LPD 29), the U.S. Navy’s 13th San Antonio-class amphibious transport dock at HII’s Ingalls Shipbuilding division. LPD 29 is named for McCool and Oja’s grandfather, Capt. Richard M. McCool Jr., a Medal of Honor recipient.Also pictured are Capt. Jeffrey Baker, prospective commanding officer, Richard M. McCool Jr. (LPD 29); Kari Wilkinson, Ingalls Shipbuilding president; and Erik Raven, under secretary of the Navy. PASCAGOULA, Miss., June 11, 2022 (GLOBE NEWSWIRE) — HII (NYSE: HII) announced today that its Ingalls Shipbuilding division christened the company’s 13th amphibious transport dock, Richard M. McCool Jr. (LPD 29), constructed for the U.S. Navy. “For nearly two decades, we have had the opportunity...

Continue reading

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

-70% overall response rate (ORR) and 30% complete response (CR) rate in peripheral T-cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) at Dose Level 3 (DL3) and above; clinical benefit for 90% of patients- -Well tolerated safety profile across all dose levels with no DLTs observed- ZUG, Switzerland and CAMBRIDGE, Mass., June 11, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today presented positive results from the Company’s ongoing Phase 1 COBALT™-LYM trial evaluating the safety and efficacy of CTX130™, its wholly-owned allogeneic CAR-T cell therapy targeting CD70 for the treatment of both solid tumors and certain hematologic malignancies. “We are very pleased with the preliminary results from our COBALT-LYM...

Continue reading

Information for the Extraordinary General Meeting of Shareholders of Snaige AB

Information for the Extraordinary General Meeting of Shareholders of Snaige AB

Provided is the additional information for the Extraordinary General Meeting of Shareholders (hereinafter – the Meeting) of Snaige AB (hereinafter – Company) which is convened on June 23rd, 2022 10 a.m. on the agenda item No. 2 .: Regarding the approval of the project of the Company’s restructuring plan. The Company’s shareholders are invited to participate in the Meeting and vote on the agenda items in writing, by filling voting ballot in advance and submitting to the Company (by address Pramones str. 6, Alytus, Lithuania). The document confirming the right to vote must also be sent together with voting ballot. Based on the COVID-19 morbidity rates in the country it is recommended to firstly consider the possibilities of receiving the General Voting Ballot and advance voting remotely, and to come to the Company’s...

Continue reading

Revival Gold Resumes Drilling the High-Grade Joss Target

Revival Gold Resumes Drilling the High-Grade Joss Target

Figure 1 Planned 2022 Joss Drill Targets TORONTO, June 11, 2022 (GLOBE NEWSWIRE) — Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) (“Revival Gold” or the “Company”), is pleased to announce that it has resumed drilling on the high-grade Joss target at the Company’s Beartrack-Arnett Gold Project (“Beartrack-Arnett”) located in Idaho, USA. Approximately 2,000 meters of core drilling in three holes are planned this summer at Joss. Drilling will focus on the continued definition and expansion of the one-kilometer trend of high-grade gold mineralization with underground mining and mill potential. High-grade intercepts from the eighteen core holes previously drilled on the Joss trend typically run from 4–11 g/t gold and are estimated to range between 1–5 meters in true width (see Revival Gold press release dated March 1st, 2021). Drilling...

Continue reading

Park Street A/S - Reduction of share capital

Park Street A/S – Reduction of share capital

With reference to company announcement of 25 April 2022 regarding the general meeting’s approval of share capital reduction, Park Street A/S hereby announces that completion of the share capital reduction has now been registered with the Danish Business Authority. The nominal value of the share capital reduction is DKK 10,338,160 corresponding to 10,338,160 shares of nominal value of DKK 1 held by Park Street A/S as treasury shares prior to the registration. Accordingly, Park Street A/S’ share capital is now reduced from DKK 67,513,732 to DKK 57,175,572. Consequently, Park Street A/S no longer holds any class A treasury shares nor any class B treasury shares. Prior to the share capital reduction, the treasury shares held by Park Street A/S corresponded to 15.31% of the company’s total share capital. In accordance with Section 31 of the...

Continue reading

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Media Release COPENHAGEN, Denmark; June 11, 2022  Epcoritamab demonstrated clinically meaningful efficacy in challenging to treat, highly refractory LBCL patients, including patients previously treated with chimeric antigen receptor (CAR) T-cell therapy Total patient population achieved overall response rate (ORR) of 63 percent and complete response (CR) of 39 percent; CAR T-naïve patients achieved 69 percent ORR and 42 percent CR; patients previously treated with CAR T achieved a 54 percent ORR and 34 percent CR Manageable safety profile consistent with previous findings was observed Results were reported as part of a late-breaking oral presentation selected for the Presidential Symposium at the EHA Annual Congress Genmab A/S (Nasdaq: GMAB) announced today primary results from the large B-cell lymphoma (LBCL) expansion cohort in the...

Continue reading

Honey Badger to Acquire 100% of the Cachinal Silver-Gold Project in Chile, with 16.3 Million Ounces of Indicated and 2.5 Million Ounces of Inferred Silver Resources

Honey Badger to Acquire 100% of the Cachinal Silver-Gold Project in Chile, with 16.3 Million Ounces of Indicated and 2.5 Million Ounces of Inferred Silver Resources

TORONTO, June 10, 2022 (GLOBE NEWSWIRE) — Honey Badger Silver Inc. (TSX-V: TUF) (“Honey Badger” or the “Company”) is pleased to announce that it has entered into a non-binding term sheet (the “Term Sheet”) to acquire from Aftermath Silver Ltd. (“Aftermath”) its 100% interest in the Cachinal De La Sierra Silver-Gold Project (the “Cachinal Project” or “Cachinal”), located in the Cachinal de la Sierra area in Chile’s Antofagasta region (Region II). The proposed transaction includes an exclusivity period that ends on August 15, 2022. Honey Badger and Aftermath are working diligently to finalize a definitive agreement on or before this date. Cachinal Project Highlights Open-pit Indicated Resource of 15.03 Moz of silver grading 97 g/t of silver and 20.05Koz of gold grading 0.13 g/t gold; Open-pit Inferred Resource of 0.41 Moz...

Continue reading

Exela Technologies Announces Dividend on Series B Preferred Stock

Exela Technologies Announces Dividend on Series B Preferred Stock

IRVING, Texas, June 10, 2022 (GLOBE NEWSWIRE) — Exela Technologies, Inc. (“Exela”) (NASDAQ: XELA, XELAP), today announced that its Board of Directors has declared the payment of a dividend on the Company’s outstanding 6.00% Series B Cumulative Perpetual Convertible Preferred Stock (“Series B Preferred Stock”). In accordance with the terms of the Series B Preferred Stock, the Board of Directors declared a dividend of $0.46 per share of Series B Preferred Stock for the quarter ending June 30, 2022 and inclusive of the 20 days in March 2022 when the Series B Preferred Stock was first issued.  This dividend is payable in cash on June 30, 2022, to Series B Preferred stockholders of record as of June 20, 2022.  About Exela Technologies Exela Technologies is a business process automation (BPA) leader, leveraging a global footprint...

Continue reading

ApartmentLove Closes Second Tranche of Non-Brokered Private Placement of Units

ApartmentLove Closes Second Tranche of Non-Brokered Private Placement of Units

NOT FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. CALGARY, Alberta, June 10, 2022 (GLOBE NEWSWIRE) — ApartmentLove Inc. (CSE: APLV) (“ApartmentLove” or the “Company”), a leading provider of online home and apartment rental marketing services catering to landlords and renters in 30-countries on 5-continents around the world, is pleased to announce that it has closed the second tranche of its previously announced non-brokered private placement of up to 10,000,000 units of the Company (“Units”) at a price of $0.15 per Unit, for gross proceeds up to a maximum of $1,500,000 (the “Private Placement”). The securities issued in connection with the Private Placement are subject to a four-month plus one day hold period, in accordance with applicable...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.